I dislike this 0 I like this
technology innovation research and development, innovation, neglected disease, funding

The third G-FINDER survey reports on 2009 global investment into research and development (R&D) of new products for neglected
diseases, and identifies early trends and patterns across the three years of global G-FINDER data. It covers:
▶ 31 neglected diseases
▶ 134 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products
▶ Platform technologies (e.g. adjuvants, delivery technologies, diagnostic platforms)
▶ All types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.


The five-year study is funded by the Bill & Melinda Gates Foundation


Some highlights:


  • $US 3.19 BILLION Investment into R&D for new neglected disease products in 2009 
  • 8.2% The increase in year-on-year funding for neglected disease R&D
  • 4 The number of neglected diseases that received less than 0.3% of global R&D funding: Buruli ulcer, trachoma, rheumatic fever and leprosy
  • $US 178 MILLION The single biggest increase in funding (from the US National Institutes of Health)
  • 9% The drop in funding for product development partnerships
  • 77% to 72% The decrease in concentration of global funding for HIV/AIDS, tuberculosis and malaria between 2007 and 2009
  • 3 The number of neglected diseases that increased their global funding share to over 5% for the first time: diarrhoeal diseases, dengue and kinetoplastids
  • 13% The percentage of global neglected disease R&D funding from the pharmaceutical industry
http://www.policycures.org/downloads/G-FINDER_Year_3_summary.pdf  
Added by John Daly on February 07, 2012

Printer friendly    Email this post    Save
    

 
Facebook
Twitter
RSS
Feedback